---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-069464"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:05:16.407389+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director Todd Foley resigns; stockholders elect Kim, Zeiher to board, ratify EY

## Summary
- Todd Foley resigned from the Board effective June 7, 2023; no disagreement with company operations.
- At 2023 Annual Meeting, Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. elected as Class II directors.
- Votes: Kim 24,512,848 for, Zeiher 24,696,429 for; broker non-votes of 1,876,971 each.
- Ratification of EY as independent auditor for FY2023 passed: 26,634,250 for, 606 against, 10 abstain.

## SEC filing metadata
- accession: 0001104659-23-069464
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/tm2318297d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-069464
- JSON: https://secwatch.observer/filing/0001104659-23-069464.json
- Plain text: https://secwatch.observer/filing/0001104659-23-069464.txt

## Key facts
- Executive change
  Todd Foley resigned as member of the Board of Directors at Entrada Therapeutics, Inc..
  - Action: resigned
  - Role: member of the Board of Directors
  source text: On June 7, 2023, Todd Foley notified Entrada Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective as of June 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm
- Shareholder Votes
  Entrada Therapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal No. 1 Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were duly elected to the Company’s Board as Class II directors. The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Peter S. Kim, Ph.D. 24,512,848 245,047 1,876,971 Bernhardt Zeiher, M.D. 24,696,429 61,466 1,876,971
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm
- Shareholder Votes
  Entrada Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal No. 2 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN 26,634,250 606 10
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.